

Jonathan M. Barasch, et al.
U.S. Serial No. : Not Yet Known
(§371 National Stage Application of
PCT/US00/12536, filed 4 May 2000)
Filed: Herewith
Page 3

Applicants maintain that the amendments made hereinabove do not raise any issue of new matter. Accordingly, applicants respectfully request entry of the Amendment.


Sequence Listing

The Sequence Listing in the subject application is identical to the Sequence Listing in the parent of the subject application, namely PCT International Application No. PCT/US00/12536, filed May 4, 2000. Applicants attach herewith copies of the paper copy of the Sequence Listing (3 pages) and the Statement In Accordance With 37 C.F.R. §1.821(f) which were filed with PCT International Application No. PCT/US00/12536 on May 4, 2000. In accordance with 37 C.F.R. §1.821 (e), please use the computer readable form filed in PCT International Application No. PCT/US00/12536 on May 4, 2000 as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee other than the filing fee of \$50.00, is deemed necessary in connection with this Preliminary Amendment. However, if any additional fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicant
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

Amended Claims:

Deletions to the text are indicated by square brackets.

10. (Amended) The method of claim [1, 4, or] 8, wherein the effective amount of the gp130 receptor ligand is an amount from about 5ng/ml to about 200 ng/ml.
12. (Amended) The method of claim [1, 3, 6, or] 8, wherein the effective amount of the gp130 receptor ligand is cardiotrophin, an oncostatin M, a cliiary neuronotrophic factor, or an interlukin-6.
13. (Amended) The method of claim [1, 3, 6, or] 8, wherein the growth factor is one or more of a TGF α , a FGF-2, a FGF-9, a TIMP-1, or a TIMP-2.
14. (Amended) The method of claim [1, 4, or] 8, wherein the growth factor is TGF α , a FGF-2, or FGF-9 and the effective amount of TGF α , a FGF-2, or FGF-9 is an amount from about 1 ng/ml to about 100 ng/ml.
16. (Amended) The method of claim [1, 4, or] 8, wherein the growth factor is TIMP-1 or TIMP-2 and the effective amount of TIMP-1 or TIMP-2 is an amount from about 200 ng/ml to about 2 μ g/ml.
18. (Amended) The method [any of] of claim[s 1, 3, 6, or] 8, wherein the gp130 receptor ligand is a polypeptide comprising a sequence identical to a naturally occurring human gp130 receptor ligand.

19. (Amended) The method [any of] of claim[s 2, 5, 7, or] 9, wherein the leukemia inhibitory factor is a polypeptide comprising a sequence identical to a naturally occurring human leukemia inhibitory factor.
20. (Amended) The method [any of] of claim[s 1, 3, 6, or] 8, wherein the growth factor is a polypeptide comprising a sequence identical to a naturally occurring human growth factor.

EXHIBIT A

Jonathan M. Barasch et al.
U.S. Serial No: Not Yet Known
(§371 National Stage Application of
PCT/US00/12536, filed 4 May 2000)
Filed: Herewith